By Microcap Daily

Axim Biotechnologies Inc (OTCMKTS: AXIM) is making a big move to the upside after the Company announced strong results for its Rapid NeuCovix™ test which was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum from patients who strongly neutralized SARS-CoV-2 and serum from patients who poorly neutralized the virus. Additionally, NeuCovix™ did not cross-react with serum from patients with seasonal respiratory infections including seasonal coronaviruses, suggesting that the test has 100 percent specificity for COVID-19.

AXIM recently unvailed its NeuCovixTM, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. The Companies CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”

Read the Full Article